Personalized Cancer Medicine Market By Product (Personalized Medicine Therapeutics, Personalized Medicine Diagnostics), By End User (Hospitals and clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The Personalized Cancer Medicine Market was valued for $179.99 billion in 2022 and is estimated to reach $507.23 billion by 2032, exhibiting a CAGR of 10.9% from 2023 to 2032. Personalized medicine, also known as precision medicine, refers to an approach in healthcare that considers an individual's unique genetic, molecular, and clinical characteristics to guide the prevention, diagnosis, and treatment of diseases, including cancer. Personalized cancer medicine involves analyzing the genetic and molecular makeup of a patient's tumor to tailor treatment strategies specific to their disease. It aims to optimize therapeutic outcomes by selecting therapies that target specific genetic alterations, biomarkers, or molecular pathways associated with the individual's cancer, thereby enhancing treatment effectiveness while minimizing potential side effects. The goal is to provide patients with personalized and targeted therapies that offer the greatest likelihood of success based on their specific cancer characteristics.
The personalized cancer medicine market growth is being driven by several key factors such as the increase in prevalence of cancer, resulting in a greater demand for effective treatment options. Precision medicine has emerged as a promising approach for treating cancer, thus driving its adoption and growth. In addition, the aging population is another factor that drives the demand for precision medicine. The geriatric population is more prone to developing cancer, creating a larger pool of potential patients. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized cancer therapies, which are likely to drive the market growth. In addition, personalized medicines have shown promising results in clinical trials, leading to increased investment in research and development activities.
Moreover, the rise in key strategies adopted by the key market players such as product launch, agreement, and collaborations further drive the growth of the market during the forecast period. For instance, on February 2021, Qiagen and Inovio Pharmaceuticals, a biotechnology company announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies.
Furthermore, a rise in approvals from regulatory organizations further provides opportunity for market growth. For instance, on October 2021, F. Hoffmann-La Roche AG , a global pioneer in pharmaceuticals and diagnostics, received U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalized healthcare. Thus, the adoption of such strategies by key manufacturers can potentially increase the demand and adoption of personalized medicine arena and provide lucrative opportunity to market growth.
However, the high cost of personalized medicines hinders the growth of the personalized medicine market. High cost of diagnosis and treatment makes it inaccessible for the patients with poor financial conditions and restrains the market in developing regions. Furthermore, many patients are unaware about the concept of personalized medicines, which acts as a restrain to the market. On the other hand, government and non-government organizations create awareness about the advanced healthcare options among the population, which may increase the adoption of personalized cancer medicines, thus, driving the market expansion during the forecast period.
The personalized cancer medicine market is segmented into product, end user, and region. By product, the market is categorized into personalized medicine diagnostics and personalized medicine therapeutics. By end user, the market is bifurcated into hospitals & clinics and others. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).
Major key players that operate in the global personalized cancer medicine market are Abbott Laboratories, ARIEL Precision Medicine, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare, Inc, Aadi Bioscience, Inc., Illumina, Inc., Qiagen, Novartis AG, Thermo Fisher Scientific Inc., Bristol-Myers Squibb Company. The key players operating in the market have adopted product approval, agreement, partnership, product launch, and collaboration as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the personalized cancer medicine market analysis from 2022 to 2032 to identify the prevailing personalized cancer medicine market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the personalized cancer medicine market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global personalized cancer medicine market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Personalized Medicine Diagnostics
Personalized Medicine Therapeutics
By End User
Hospitals and clinics
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
Rest of Asia-Pacific
LAMEA
Latin America
Middle East And Africa
Key Market Players
Aadi Bioscience, Inc.
Abbott Laboratories
ARIEL Precision Medicine, Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
General Electric
Illumina, Inc.
Novartis AG
Qiagen NV.
Thermo Fisher Scientific Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of cancer
- 3.4.1.2. Increase in demand for ideal therapeutics for treatment
- 3.4.1.3. Rise in adoption of Artificial Intelligence (AI) based diagnosis
- 3.4.2. Restraints
- 3.4.2.1. High cost of personalized medicine
- 3.4.2.2. Limited Reimbursement and coverage
- 3.4.3. Opportunities
- 3.4.3.1. Increase in R&D activities in personalized cancer medicine
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Personalized Medicine Therapeutics
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Personalized Medicine Diagnostics
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: PERSONALIZED CANCER MEDICINE MARKET, BY END USER
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Hospitals and clinics
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Others
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: PERSONALIZED CANCER MEDICINE MARKET, BY REGION
- 6.1. Overview
- 6.1.1. Market size and forecast By Region
- 6.2. North America
- 6.2.1. Key trends and opportunities
- 6.2.2. Market size and forecast, by Product
- 6.2.3. Market size and forecast, by End User
- 6.2.4. Market size and forecast, by country
- 6.2.4.1. U.S.
- 6.2.4.1.1. Key market trends, growth factors and opportunities
- 6.2.4.1.2. Market size and forecast, by Product
- 6.2.4.1.3. Market size and forecast, by End User
- 6.2.4.2. Canada
- 6.2.4.2.1. Key market trends, growth factors and opportunities
- 6.2.4.2.2. Market size and forecast, by Product
- 6.2.4.2.3. Market size and forecast, by End User
- 6.2.4.3. Mexico
- 6.2.4.3.1. Key market trends, growth factors and opportunities
- 6.2.4.3.2. Market size and forecast, by Product
- 6.2.4.3.3. Market size and forecast, by End User
- 6.3. Europe
- 6.3.1. Key trends and opportunities
- 6.3.2. Market size and forecast, by Product
- 6.3.3. Market size and forecast, by End User
- 6.3.4. Market size and forecast, by country
- 6.3.4.1. Germany
- 6.3.4.1.1. Key market trends, growth factors and opportunities
- 6.3.4.1.2. Market size and forecast, by Product
- 6.3.4.1.3. Market size and forecast, by End User
- 6.3.4.2. France
- 6.3.4.2.1. Key market trends, growth factors and opportunities
- 6.3.4.2.2. Market size and forecast, by Product
- 6.3.4.2.3. Market size and forecast, by End User
- 6.3.4.3. UK
- 6.3.4.3.1. Key market trends, growth factors and opportunities
- 6.3.4.3.2. Market size and forecast, by Product
- 6.3.4.3.3. Market size and forecast, by End User
- 6.3.4.4. Italy
- 6.3.4.4.1. Key market trends, growth factors and opportunities
- 6.3.4.4.2. Market size and forecast, by Product
- 6.3.4.4.3. Market size and forecast, by End User
- 6.3.4.5. Spain
- 6.3.4.5.1. Key market trends, growth factors and opportunities
- 6.3.4.5.2. Market size and forecast, by Product
- 6.3.4.5.3. Market size and forecast, by End User
- 6.3.4.6. Rest of Europe
- 6.3.4.6.1. Key market trends, growth factors and opportunities
- 6.3.4.6.2. Market size and forecast, by Product
- 6.3.4.6.3. Market size and forecast, by End User
- 6.4. Asia-Pacific
- 6.4.1. Key trends and opportunities
- 6.4.2. Market size and forecast, by Product
- 6.4.3. Market size and forecast, by End User
- 6.4.4. Market size and forecast, by country
- 6.4.4.1. Japan
- 6.4.4.1.1. Key market trends, growth factors and opportunities
- 6.4.4.1.2. Market size and forecast, by Product
- 6.4.4.1.3. Market size and forecast, by End User
- 6.4.4.2. China
- 6.4.4.2.1. Key market trends, growth factors and opportunities
- 6.4.4.2.2. Market size and forecast, by Product
- 6.4.4.2.3. Market size and forecast, by End User
- 6.4.4.3. Australia
- 6.4.4.3.1. Key market trends, growth factors and opportunities
- 6.4.4.3.2. Market size and forecast, by Product
- 6.4.4.3.3. Market size and forecast, by End User
- 6.4.4.4. Rest of Asia-Pacific
- 6.4.4.4.1. Key market trends, growth factors and opportunities
- 6.4.4.4.2. Market size and forecast, by Product
- 6.4.4.4.3. Market size and forecast, by End User
- 6.5. LAMEA
- 6.5.1. Key trends and opportunities
- 6.5.2. Market size and forecast, by Product
- 6.5.3. Market size and forecast, by End User
- 6.5.4. Market size and forecast, by country
- 6.5.4.1. Latin America
- 6.5.4.1.1. Key market trends, growth factors and opportunities
- 6.5.4.1.2. Market size and forecast, by Product
- 6.5.4.1.3. Market size and forecast, by End User
- 6.5.4.2. Middle East And Africa
- 6.5.4.2.1. Key market trends, growth factors and opportunities
- 6.5.4.2.2. Market size and forecast, by Product
- 6.5.4.2.3. Market size and forecast, by End User
- CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top player positioning, 2022
- CHAPTER 8: COMPANY PROFILES
- 8.1. Abbott Laboratories
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
- 8.2. ARIEL Precision Medicine, Inc.
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.3. F. Hoffmann-La Roche Ltd.
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
- 8.3.7. Key strategic moves and developments
- 8.4. General Electric
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
- 8.5. Aadi Bioscience, Inc.
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
- 8.6. Illumina, Inc.
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
- 8.7. Qiagen NV.
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
- 8.7.7. Key strategic moves and developments
- 8.8. Novartis AG
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.9. Thermo Fisher Scientific Inc.
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
- 8.10. Bristol-Myers Squibb Company
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 02. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2022-2032 ($BILLION)
- TABLE 03. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2022-2032 ($BILLION)
- TABLE 04. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 05. PERSONALIZED CANCER MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($BILLION)
- TABLE 06. PERSONALIZED CANCER MEDICINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
- TABLE 07. PERSONALIZED CANCER MEDICINE MARKET, BY REGION, 2022-2032 ($BILLION)
- TABLE 08. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 09. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 10. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
- TABLE 11. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 12. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 13. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 14. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 15. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 16. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 17. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 18. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 19. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
- TABLE 20. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 21. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 22. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 23. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 24. UK PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 25. UK PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 26. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 27. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 28. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 29. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 30. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 31. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 32. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 33. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 34. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
- TABLE 35. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 36. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 37. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 38. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 39. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 40. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 41. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 42. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 43. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 44. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 45. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
- TABLE 46. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 47. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 48. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
- TABLE 49. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
- TABLE 50. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 51. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 52. ABBOTT LABORATORIES: PRODUCT SEGMENTS
- TABLE 53. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 54. ARIEL PRECISION MEDICINE, INC.: KEY EXECUTIVES
- TABLE 55. ARIEL PRECISION MEDICINE, INC.: COMPANY SNAPSHOT
- TABLE 56. ARIEL PRECISION MEDICINE, INC.: PRODUCT SEGMENTS
- TABLE 57. ARIEL PRECISION MEDICINE, INC.: PRODUCT PORTFOLIO
- TABLE 58. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 59. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 60. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 61. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 62. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 63. GENERAL ELECTRIC: KEY EXECUTIVES
- TABLE 64. GENERAL ELECTRIC: COMPANY SNAPSHOT
- TABLE 65. GENERAL ELECTRIC: SERVICE SEGMENTS
- TABLE 66. GENERAL ELECTRIC: PRODUCT PORTFOLIO
- TABLE 67. GENERAL ELECTRIC: KEY STRATERGIES
- TABLE 68. AADI BIOSCIENCE, INC.: KEY EXECUTIVES
- TABLE 69. AADI BIOSCIENCE, INC.: COMPANY SNAPSHOT
- TABLE 70. AADI BIOSCIENCE, INC.: PRODUCT SEGMENTS
- TABLE 71. AADI BIOSCIENCE, INC.: PRODUCT PORTFOLIO
- TABLE 72. AADI BIOSCIENCE, INC.: KEY STRATERGIES
- TABLE 73. ILLUMINA, INC.: KEY EXECUTIVES
- TABLE 74. ILLUMINA, INC.: COMPANY SNAPSHOT
- TABLE 75. ILLUMINA, INC.: PRODUCT SEGMENTS
- TABLE 76. ILLUMINA, INC.: PRODUCT PORTFOLIO
- TABLE 77. ILLUMINA, INC.: KEY STRATERGIES
- TABLE 78. QIAGEN NV.: KEY EXECUTIVES
- TABLE 79. QIAGEN NV.: COMPANY SNAPSHOT
- TABLE 80. QIAGEN NV.: PRODUCT SEGMENTS
- TABLE 81. QIAGEN NV.: PRODUCT PORTFOLIO
- TABLE 82. QIAGEN NV.: KEY STRATERGIES
- TABLE 83. NOVARTIS AG: KEY EXECUTIVES
- TABLE 84. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 85. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 86. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 87. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
- TABLE 88. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- TABLE 89. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
- TABLE 90. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
- TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
- TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. PERSONALIZED CANCER MEDICINE MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF PERSONALIZED CANCER MEDICINE MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN PERSONALIZED CANCER MEDICINE MARKET (2023-2032)
- FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW THREAT OF NEW ENTRANTS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. MODERATE INTENSITY OF RIVALRY
- FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPERSONALIZED CANCER MEDICINE MARKET
- FIGURE 09. PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022(%)
- FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. PERSONALIZED CANCER MEDICINE MARKET BY REGION, 2022
- FIGURE 16. U.S. PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 17. CANADA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 18. MEXICO PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 19. GERMANY PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 20. FRANCE PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 21. UK PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 22. ITALY PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 23. SPAIN PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 24. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 25. JAPAN PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 26. CHINA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 27. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 28. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 29. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 30. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
- FIGURE 31. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 35. COMPETITIVE DASHBOARD
- FIGURE 36. COMPETITIVE HEATMAP: PERSONALIZED CANCER MEDICINE MARKET
- FIGURE 37. TOP PLAYER POSITIONING, 2022
- FIGURE 38. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
- FIGURE 39. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 40. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 41. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
- FIGURE 42. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 43. GENERAL ELECTRIC: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 44. GENERAL ELECTRIC: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 45. GENERAL ELECTRIC: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 46. AADI BIOSCIENCE, INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 47. ILLUMINA, INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 48. ILLUMINA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 49. ILLUMINA, INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 50. QIAGEN NV.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 51. QIAGEN NV.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 52. QIAGEN NV.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 53. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 54. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 55. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 56. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 57. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 58. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 59. BRISTOL-MYERS SQUIBB COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 60. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook